The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.

On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

KELOWNA, BC / ACCESSWIRE / October 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, provides an update on ...

KELOWNA, BC / ACCESSWIRE / October 8, 2024 / (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator ...

IMS 2024 Isatuximab Quadruplet Approval Could Change MM Landscape IMTOZ trial findings and subsequent approval of Isa-VRd regimen for transplant-ineligible myeloma suggested the combo as a new ...

Like semaglutide—the drug behind Ozempic and Wegovy—tirzepatide is taken by injections and helps reduce appetite. So, did it work for Bunnie? "I woke up a pound and a half lighter," she noted ...

Thousands of patients came to rely on knockoff versions of drugs made with tirzepatide after shortages began as early as 2022. The US Food and Drug Administration allows ... Tirzepatide injections ...

Thursday, The FDA determined the shortage of Eli Lilly And Co’s LLY tirzepatide injection ... compounding regulations and respects branded drug patents. Based on third-quarter card data analysis ...

Semaglutide and tirzepatide ... those who had injections. However, the patients in the tirzepatide group were able to reduce the amount of insulin they took. When their lower body weight was taken ...

NHS England has asked NICE to consider approving a slow phased rollout of tirzepatide (Mounjaro) for weight loss in primary care to avoid overwhelming GPs. It follows draft recommendations from NICE ...